Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | IARS1 | P41252 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730705 | 1.00 | F10 (0.35) | F10IARS1 | |
| SCHEMBL12892710 | 1.00 | F10 (0.35) | F10IARS1 | |
| SCHEMBL15883973 | 0.86 | SERPINC1 (0.36) | F10 | |
| SCHEMBL18174832 | 0.86 | SERPINC1 (0.36) | F10 | |
| SCHEMBL12355191 | 0.85 | IARS1 (0.33) | F10IARS1 | |
| SCHEMBL9976875 | 0.85 | IARS1 (0.33) | F10IARS1 | |
| SCHEMBL14478983 | 0.85 | IARS1 (0.33) | F10IARS1 | |
| SCHEMBL6123884 | 0.84 | F10 (0.30) | F10IARS1 | |
| SCHEMBL13692694 | 0.81 | F10 (0.30) | F10 | |
| SCHEMBL12346246 | 0.80 | F10 (0.35) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879361-B2 | composed of chitosan, poly-glutamic acid substrate, and bioactive agent of HMG-CoA reductase inhibitors or erythropoietin; positive surface charge and enhanced permeability for paracellular drug delivery | GP MEDICAL, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7541028-B2 | Nanoparticles for monoclonal antibody delivery | GP MEDICAL, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20070237831-A1 | Nanoparticles for monoclonal antibody delivery | NANOMEGA MEDICAL CORPORATION | 2007-10-11 | — | — | US | disclosed |
| US-20070237827-A1 | Nanoparticles for drug delivery | NANOMEGA MEDICAL CORPORATION | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070237831-A1 | Nanoparticles for monoclonal antibody delivery | EPCAM, CA12, CA14 | F10 1639/4885IARS1 2518/4885 |
| US-20070237827-A1 | Nanoparticles for drug delivery | EPOR, HMGCR, LDLR | F10 2021/4885IARS1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.